The 2025 Medicare Physician Fee Schedule final rule, released Nov. 1, includes a conversion factor of $32.3465, a 2.83% drop from 2024. In response to advocacy efforts from the ACR and other medical societies, Congress recently introduced the Medicare Patient Access and Practice Stabilization Act of 2024, which would eliminate the 2.83% payment cut and provide an inflationary update for 2025 equal to 50% of the Medicare Economic Index.
Search results for: biosimilars
Updates from the ACR Insurance Subcommittee
The ACR Insurance Subcommittee (ISC) of the Committee on Rheumatologic Care has been hard at work, advocating to payers on behalf of the ACR and its members. Following is an update on some of the work this group has been doing to help address concerns about reimbursement and administrative burden, while ensuring continued access to…
ACR Convergence 2024 Preview: Key Business Takeaways
In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.
Spotlight on Pediatric Rheumatology in Singapore
A pioneer of pediatric rheumatology in Singapore, Dr. Elizabeth Ang details her unique clinical experiences.
Affiliate Society Council Active & Reenergized, Reports Chair Gwenesta B. Melton, MD
ASC Chair Gwenesta B. Melton, MD, shares the connections and activities that are helping the council develop stronger ties in and outside the ACR.
How the ACR Helps with Reimbursement, Utilization Management & Other Practice Challenges
Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.
Empowered Patients
This year’s theme for Rheumatic Disease Awareness Month focuses on self-management, aiming to provide tools and tips to empower patients, boost awareness about the importance of self-management and, ultimately, improve patient outcomes.
Draft FDA Guidance No Longer Requires Biosimilar Switching Studies
The updated draft guidance, released in June, would accept an assessment of why data provided meet the switching standard to demonstrate interchangeability of biosimilars
AWIR & ACR: Building a Strong Future Rheumatology Community
The ACR was fortunate to participate in the Association for Women in Rheumatology’s 2024 Annual Meeting in Orlando. As this relationship grows every year, the AWIR and ACR are working together to build a sustainable and inclusive rheumatology community for the future.
Meet the ACR’s Advocacy Team
It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 32
- Next Page »